Biomarkers are revolutionizing the treatment landscape for NSCLC
More focus is needed on subtypes of lung cancer that do not have FDA-approved targeted therapies
Pembrolizumab and the significance of PD-L1 for lung cancer
Quality of life and symptom control for non-squamous NSCLC patients on nivolumab (CheckMate 057)
Durvalumab: the new standard of care for NSCLC?